Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional Results available

Neurobehavioral Mechanisms of Choice in Opioid Use Disorder

NCT03958474
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Oxycodone
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence

NCT03653897
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ID-Capsule- Active, Wearable Sensor
Device
Lead sponsor
EtectRX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 22, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)

NCT01750918
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 9:32 AM EDT
Terminated Phase 1 Interventional

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

NCT02235740
View directory record Official record
Conditions
Cancer
Interventions
Afuresertib, Carfilzomib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 22, 2026, 9:32 AM EDT
Terminated Phase 1 Interventional

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT04155580
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ASTX660, ASTX727
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery

NCT03123068
View directory record Official record
Conditions
Surgical Recovery
Interventions
CocoaVia®, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

NCT06150560
View directory record Official record
Conditions
Coarctation of Aorta, High Blood Pressure
Interventions
Losartan, Amlodipine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
22
States / cities
Glendale, Arizona • Glendale, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Medication for Improved Analgesia in Superficial Pain

NCT02194088
View directory record Official record
Conditions
Pain
Interventions
Diclofenac and Atropine combination drug, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

NCT01581203
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

TD-6450 MAD Study in HCV Infected Subjects

NCT02116543
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 22, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

NCT03530293
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
48
States / cities
Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.

NCT01995643
View directory record Official record
Conditions
Polyphenolic Compounds and Metabolism
Interventions
Active Capsule, Placebo Capsule
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 22, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)

NCT06133231
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, Irritable Mood
Interventions
Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT03527472
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Memantine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Investigation of Nicotine Seeking Behavior in Current Smokers

NCT03670212
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Yohimbine Hydrochloride, Hydrocortisone, Lactose Monohydrate Powder
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 22, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Study of the Fecal Microbiome in Patients With Parkinson's Disease

NCT03671785
View directory record Official record
Conditions
Parkinson Disease
Interventions
PRIM-DJ2727, Placebo oral capsule
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
55 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 22, 2026, 9:32 AM EDT